Early diagnosis of Alzheimer's disease in blood using a disposable electrochemical microfluidic platform.

08:00 EDT 24th March 2020 | BioPortfolio

Summary of "Early diagnosis of Alzheimer's disease in blood using a disposable electrochemical microfluidic platform."

Alzheimer's disease (AD) is a neurodegenerative condition that affects a large number of elderly people worldwide and has a high social and economic impact. The diagnosis of AD in its early stage can significantly improve the patients' quali-ty of life. We report the use of A Disintegrin And Metalloprotease 10 (ADAM10) as a blood biomarker for the early diag-nosis of AD. A simple, low-cost, sensitive, and disposable microfluidic platform (DµP) was developed for ADAM10 detec-tion in plasma and cerebrospinal fluid (CSF) based on electrochemical immunosensors. The assay was designed to accu-rately detect ADAM10 in serum, with a limit of detection of 0.35 fg/mL. ADAM10 was detected in subjects divided into cognitively healthy subjects, subjects with mild cognitive impairment (MCI), and AD patients in different disease stages. An increase in protein levels was found throughout the disease, and good DµP accuracy in differentiating individuals was observed. The DµP provided significantly better sensitivity than the well-established enzyme-linked immunosorbent as-say (ELISA) test. ADAM10 and its detection using the DµP was proven to be an alternative tool for the early diagnosis and monitoring of AD, bringing new exciting possibilities to the ability to improve the quality of life of AD patients.


Journal Details

This article was published in the following journal.

Name: ACS sensors
ISSN: 2379-3694


DeepDyve research library

PubMed Articles [33471 Associated PubMed Articles listed on BioPortfolio]

Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls.

Collection of cerebrospinal fluid (CSF) for measurement of amyloid-β (Aβ) species is a gold standard in Alzheimer's disease (AD) diagnosis, but has risks. Thus, establishing a low-risk blood Aβ tes...

Colorimetric Paper-Based Immunosensor for Simultaneous Determination of Fetuin B and Clusterin Towards Early Alzheimer's Diagnosis.

Alzheimer's disease is a devastating condition characterized by a progressive and slow brain decay in elders. Here, we developed a paper-based lateral flow immunoassay for simultaneous and fast determ...

Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer's disease.

The development of blood-based biomarkers for early diagnosis and treatment of Alzheimer's disease (AD) is desirable. In AD model mouse brain and neuronal cells, Abelson helper integration site-1 (AHI...

Current opinion neurology: visual pathway biomarkers in Alzheimer's disease.

The incidence of Alzheimer's disease is increasing. Premortem diagnosis of Alzheimer's disease is now possible but require invasive and expensive testing such as PET amyloid beta binding and/or spinal...

Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?

Alzheimer's disease (AD) is an incurable neurodegenerative disease characterized by progressive decline of cognitive abilities. Amyloid beta peptides (Aβ), Tau proteins and the phosphorylated form of...

Clinical Trials [20577 Associated Clinical Trials listed on BioPortfolio]

A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease

The prevalence of Mild Cognitive Impairment (MCI) is about 15%-17%. 10%-15% of MCI progresses to Alzheimer's disease (AD) every year. The annual incidence of MCI in the normal elderly is a...

Blood Biomarker of Alzheimer's Disease (AD)

Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage wher...

DECODING Study (Dermal Electrochemical Conductance in Diabetic Neuropathy)

Diabetes mellitus is the leading cause of polyneuropathy in the Western world. Diabetic neuropathy is a frequent complication of diabetes and may have great clinical transcendence due to p...

An Efficacy and Safety Study of AZD3293 in Early Alzheimer's Disease

The purpose of this study is to assess the efficacy and safety of AZD3293 compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. The study will te...

Longitudinal Early-onset Alzheimer's Disease Study Protocol

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early o...

Medical and Biotech [MESH] Definitions

Methods to determine in patients the nature of a disease or disorder at its early stage of progression. Generally, early diagnosis improves PROGNOSIS and TREATMENT OUTCOME.

Integral membrane protein of Golgi and endoplasmic reticulum. Its homodimer is an essential component of the gamma-secretase complex that catalyzes the cleavage of membrane proteins such as NOTCH RECEPTORS and AMYLOID BETA-PROTEIN precursors. PSEN1 mutations cause early-onset ALZHEIMER DISEASE type 3 that may occur as early as 30 years of age in humans.

Analyses for a specific enzyme activity, or of the level of a specific enzyme that is used to assess health and disease risk, for early detection of disease or disease prediction, diagnosis, and change in disease status.

A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe MENTAL RETARDATION. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)

A scanning probe microscopy technique that uses an ultramicroelectrode as the scanning probe that simultaneously records changes in electrochemical potential as it scans thereby creating topographical images with localized electrochemical information.

Quick Search

DeepDyve research library

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Searches Linking to this Article